top of page
old-woman-with-cancer-is-sitting-wheelch
Our research with Circulating Tumor Cells aims to identify this type of cell by analyzing a minimum blood value. In 2016 we were already able to detect these cells using our portable device IG11.

​

​

WHAT ARE CIRCULATING TUMOR CELLS

​

Circulating tumor cells (CTCs) are a rare subset of cells found in the blood of patients with solid tumors, they are shed from tumors and circulate in the bloodstream, which function as a seed for metastases. Cancer cells metastasize through the bloodstream either as single migratory CTCs or as multicellular groupings—CTC clusters. This process can also occur at an early stage of cancer.

​

Our research aims  not just indicate the presence of a tumor but also to provide with its core information. 

​

The major limitation in isolation of CTCs is their availability in limited numbers . These cells have tremendous potential for assessing the stage of cancer development and for monitoring treatment. 

 

​

BENIGN VS. MALIGNANT TUMOR

​

A benign tumor does not invade its surrounding tissue or spread around the body, in this case the presence of circulating tumor cells (CTC)  in the peripheral blood can theoretically anticipate malignancy of cancer in a variety of organs. 

 

A malignant tumor may invade its surrounding tissue, wreaking havoc on its path to metastasis, it doesn't stays contained within the original site.  

​

​

THE EARLY DETECTION

​

Early diagnosis of cancer focuses on detecting symptomatic patients as early as possible so they more likely to survive, have the best chance for successful treatment and  importantly also to have better experiences of care, lower treatment morbidity and and lower costs of procedures.

​

​

QUANTIQUN RESEARCH

​

Our research works on the chemical and physical identification of CTCs through the use of nanotechnology and microscopy techniques.

​

CTCs are rare cells and for that reason the reduction of blood volume for the detection of the disease can increase the chances of error, as in this case we would be adding the factor of the probability of finding CTC within that sample volume. To address this problem, we added new materials in the new version of IG11 and used complementary techniques for lateral measurements that can withstand the shortcomings of direct measurement in samples with low volumes.

​

​

​

​

​

IG11- Next Generation

1.

Minimal amount of sample.

2.

Minimal invasive procedure.

3.

Portable and easy to use device .

4.

Multiple tests  performed with the same device.
bottom of page